AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Aug - Investor/analyst meetings with Elara Capital on 3 September 2026 in Mumbai.
Source: Bse
Sumitomo Chemical India Limited (SUMICHEM)
Large CapChemicals stocks · Large cap · NSE
Sumitomo Chemical India Limited (SCIL) is an agrochemical company offering crop protection solutions, animal nutrition, and environmental health products. It operates 5 manufacturing facilities, boasts 200+ brands, and has a wide distribution network across India, supported by R&D and parent company expertise.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals14 Oct 2026 · screener
Latest result27 Jul, 07:12 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags15 Aug 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Chemicals P/E 33.1 (n=45)
Technical timing lens
Trend score and candlestick chart
41NeutralSMA20 -14.2% / mo · RSI oversold · MACD + · near 52W low · sector -4.2pp vs Nifty 500 (3M)
Stock trend: 38
Sector RS: 46
Sector 3M: -9.8% vs Nifty 500 -5.6%
Chemicals FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
SUMICHEMD candles · FIT view-9.7%Latest close ₹392.35 on 2026-10-19
Bar
-2.9%
RSI
23
MACD hist
0.01
52W pos
14%
2026-10-19O ₹404.00H ₹404.05L ₹391.00C ₹392.35Vol 1.6L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SUMICHEMNifty ChemicalsNifty 500
- SUMICHEM
- -27.4%
- Nifty 500
- -5.6%
- Nifty Chemicals
- -8.5%
- Vs Nifty 500
- -21.9 pp
Chart stats
19 Oct 2026- From 52W high
- -31.4%
- 52W range position
- 14%
- ATR (14)
- 3.8%
- Volume vs 20D
- 0.44x
- Avg traded value
- ₹14.5 Cr
- 20D price channel
- ₹391 - ₹468
₹572.1
₹362.6 - ₹572.1
₹15.1
Latest completed session
20-session average
26.6% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend argues for patience, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST44
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good70
Revenue +0.6% · PAT +20.8% YoY
Technical
Neutral41
Price trend and sector-relative-strength timing.
Valuation
Legacy model-72.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence79
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 70/100Rev +1% YoY · PAT +21% YoY · margin expansion · +55% QoQ · operating leverage
Filed 27 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,063 Cr | +0.6% | +55.4% |
| EBITDA | ₹233 Cr | +6.4% | +73.9% |
| Operating margin | 22.0% | +100 bps | +200 bps |
| PAT | ₹215 Cr | +20.8% | +93.7% |
| PAT margin | 20.2% | +339 bps | +400 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 35.30
- P/B
- 5.95
- EV/EBITDA
- 26.89
- Market Cap
- 20187.00Cr
Profitability
- ROE
- 16.20%
- ROCE
- 22.10%
- ROA
- 12.94%
- Dividend Y
- 0.32%
Growth (CAGR)
- Revenue 5Y
- 4.00%
- EPS 5Y
- 8.00%
- Revenue 3Y
- -3.00%
- EPS 3Y
- 2.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- 85.63×
- Altman Z
- 8.41
- Book Value
- 67.90
Cash Flow
- FCF Yield
- 0.56%
- FCF Positive Y
- 8/5
- OCF
- 446.00 Cr
- EPS TTM
- 11.61
Shareholding
- Promoter Hold
- 75.00%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 20%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 3,245+0.2% vs prev
Net Profit
₹ CrLatest: 543+7.3% vs prev
Return on Equity
%Latest: 109+628.9% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 23. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~16.6% over last month) — short-term momentum negative.
- RSI(14) at 23 — oversold zone; bounce conditions.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 31% off 52W high · 8% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
20
RS percentile
Stage 1 Base / Transition
1M return
-14.9%
3M return
-27.4%
6M return
-11.7%
1Y return
-23.4%
RS 1D
-2
RS 20D
-26
Sector rank
#13
Industry rank
-
Stage evidence
- Price is 15.9% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +0.9% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
neutral
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 76.17-2.06%
RS vs Nifty 50076
Valuation & peers
U-Score 44 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 44 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation1/30
Growth9/25
Quality12/20
Balance Sheet11/15
Cash Flow6/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
44
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
44/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 11/15 to the score.
- Quality contributes 12/20 to the score.
Main drags
- Fair-value margin of safety is negative at -72.8%.
- Valuation is weaker at 1/30; verify the latest quarterly trend.
- Growth is weaker at 9/25; verify the latest quarterly trend.
Sector valuation model
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
35.3
PB
6.0
EV/EBITDA
26.9
ROE
16.2%
ROCE
22.1%
FCF Yield
0.6%
Debt/Equity
0.0
MoS
-72.8%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
44
Previous: 44
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-72.8%
Previous: -72.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
43
43
43
44
44
44
44
44
44
44
44
44
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹133.18
-194.6% MoS
Growth-justified P/E
19.6
Growth-justified Value
₹226.98
-72.8% MoS
PEG
6.30
Comparable companies
Peers
Business-comparable peers in Chemicals — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
PCBL
Large
PCBL Chemical Limited
Fertilizers & Agrochemicals
match 167
28
45.0
5.6%
-906%
OVERVALUED
KANSAINER
Micro
Kansai Nerolac Paints Limited
Fertilizers & Agrochemicals
match 163
38
22.5
8.8%
-176%
WATCHLIST
PRIVISCL
Micro
Privi Speciality Chemicals Limited
Fertilizers & Agrochemicals
match 161
66
38.0
26.0%
+18%
UNDERVALUED
SUDARSCHEM
Micro
Sudarshan Chemical Industries Limited
Fertilizers & Agrochemicals
match 159
24
89.6
0.5%
-8507%
OVERVALUED
NEOGEN
Micro
Neogen Chemicals Limited
Fertilizers & Agrochemicals
match 157
9
216.0
3.6%
-2868%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-06-13T08:24:46.369Z
Management commentary snapshot
FY26 revenue grew 3% YoY to Rs. 3,238 crore, with PAT up 7% YoY to Rs. 543 crore, achieving highest-ever profitability despite industry headwinds. Q4FY26 revenue was broadly stable YoY, while PAT increased 12% YoY.
SCIL demonstrated remarkable stability and delivered its highest-ever profitability in FY26, driven by favorable product mix, disciplined pricing, and strong execution. This performance was achieved despite significant industry headwinds, indicating robust operational management and a resilient business model.
Current business mix
Revenue by Product (FY26)
Latest issuer-disclosed distribution across 6 reported categories.
Insecticides40.0%
Herbicides11.0%
PGR9.0%
Metal Phosphides9.0%
Fungicides10.0%
AND & EHD21.0%
Growth engines
New Product Launches
Newly launched products like Lentigo, Excalia Max, Powerpull, Advika, Envoy, and Oslava received encouraging market response.
Herbicides Portfolio
Registered strong growth of 87% YoY in Q4FY26 and 19% YoY in FY26, supported by healthy traction in rice herbicide portfolio including Lentigo.
Africa Exports
Continued strong momentum with 30% YoY growth in Q4FY26 and 26% YoY growth in FY26.
Strategic Manufacturing Hub
Dahej site is being developed as a strategic global manufacturing hub for the parent company’s high-potential patented molecules.
Capacity and execution
Herbicide Intermediate Plant at Dahej
Capex budget: ~Rs 150 crore. Estimated commercialization: Q2 FY2028-29. First strategic investment at Dahej site for parent company supply.
Fitment for Additional Products at Tarapur
Capex budget: ~Rs 10 crore. Estimated commercialization: Q4 FY2027-28. To manufacture two additional molecules (fungicide, herbicide) for parent company supply.
Second Plant for SCC Innovated Product at Bhavnagar
Investment: Approximately ₹55 crore. Target completion & commercialization: Q4FY27. To meet global requirements and build on first plant's success.
Production of Newly Launched SCC Innovated Molecule at Tarapur
Investment: Around ₹10 crore. Target completion & commercialization: Q4FY27. To demonstrate SCIL’s capability and meet domestic demand.
Tailwinds
Favorable Product Mix
Contributed to margin expansion and highest-ever profitability in FY26.
Calibrated Pricing Actions
Supported margin improvement and business stability despite industry challenges.
Strong Execution Focus
Helped maintain business stability through disciplined channel management and operational agility.
Headwinds
Challenging Agrochemical Industry
Prolonged/excess rainfall, delayed rabi demand recovery, bio-stimulant regulatory challenges, and cautious channel sentiments.
Lower Contribution from Low-Margin Business
Lower contribution from the Animal Nutrition (AND) distribution business impacted overall revenue growth.
Softer Agri-input Demand
Contributed to industry-wide challenges and impacted revenue.
Softer Export Demand
Led to a decline in overall export revenues due to softer demand and shipment delays in select geographies.
Risk radar
Weather Conditions & El-Nino
Management remains cautiously optimistic while remaining watchful of weather conditions and El-Nino related uncertainties.
Raw Material Inflation
Management is watchful of raw material inflation as a potential challenge.
Geopolitical Developments
Management is cautiously optimistic but watchful of geopolitical developments.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
The company explicitly states annual monitoring is best due to seasonality. However, quarterly results are provided and useful for assessing recent momentum and the impact of specific market conditions.
Sector KPIs management disclosed
Revenue from Operations
FY26: Rs. 3,238.3 Cr (+3% YoY); Q4FY26: Rs. 683.7 Cr (+1% YoY)
Gross Profit Margin
FY26: 42.0% (+107 bps YoY); Q4FY26: 42.3% (+223 bps YoY)
EBITDA Margin
FY26: 20.7% (+64 bps YoY); Q4FY26: 19.6% (+202 bps YoY)
PAT Margin
FY26: 16.8% (+68 bps YoY); Q4FY26: 16.3% (+159 bps YoY)
Management forward view
Focus on Profitability-led Growth
The company maintained strong operational discipline throughout FY26 with continued focus on profitability-led growth.
Demand Generation & Differentiated Offerings
Management continues to focus on demand generation and differentiated product offerings to drive sustainable and profitable growth in FY27.
Strengthening Channel Partnerships
The company aims to strengthen channel partnerships to drive sustainable and profitable growth in FY27.
Developing Dahej as Global Manufacturing Hub
The first strategic investment at Dahej marks a key step in developing it as a strategic global manufacturing hub for parent company’s patented molecules.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Net Working Capital Days | 103 days (FY26) | Improvement towards FY25 level (89 days) and efficient management of seasonal inventory build-up. |
| Export Revenue Growth | -1% YoY (FY26) | Recovery in demand and successful execution of shipments in select geographies, particularly beyond Africa. |
| New Product Pipeline & Launches | Encouraging market response for recent launches | Sustained traction and increasing contribution of new products to overall revenue and profitability. |
| Capex Project Commercialization | Multiple projects approved with timelines up to Q2 FY2028-29 | On-schedule commissioning and ramp-up of new capacities, especially the strategic Dahej plant. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
79Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 88th percentile of the scored universe and 81st percentile within Chemicals. Main check: results consistency is weak at 55/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 21 Oct 2026
management-trust-v1
80 docs text-extracted · 23 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
88th percentile
overall median 67 · Chemicals: 81st pctile, median 73 · Large: 74th pctile, median 73
Evidence depth
Financial-only
80 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
74
acceptable · capital discipline
Results
55
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 75%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.6%.
- ▸8 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Sumitomo Chemical India Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Management 26 May - Dr. Suresh Ramachandran promoted to Managing Director from 1 September 2026, subject to shareholder approval.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Aug - Company will meet investors on 19 August 2026 at 3:00 pm in Mumbai, hosted by Motilal Oswal.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Dividend Updates 26 May - Board declared ₹1.30 per share FY 2025-26 dividend, payable on or after 3 August 2026.
Source: Bse
Investor presentationJul 2026
Jul 2026 · PPT
Source: Bse
Annual reportJul 2026
Jul 2026 · Reg. 34 (1) Annual Report. 3 Jul - FY26 annual report filed; PAT ₹543 crore, dividend ₹1.30/share, AGM on 27 July 2026, leadership transition proposed.
Source: Bse
Annual reportJul 2026
Jul 2026 · Reg. 34 (1) Annual Report. 2 Jul - FY26 annual report: revenue ₹3,238 crore, PAT ₹543 crore, dividend ₹1.30; AGM on 27 July 2026.
Source: Bse
Annual reportJul 2026
Jul 2026 · Reg. 34 (1) Annual Report. 1d - FY26 annual report: PAT ₹543 crore, dividend ₹1.30, AGM 27 Jul 2026; proposed MD change from 1 Sep 2026.
Source: Bse
Investor presentationJun 2026
Jun 2026 · PPT
Source: Bse
Concall transcriptJun 2026
Jun 2026 · Transcript
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 28 May - Earnings call scheduled for 28 May 2026 at 2:00 pm to discuss FY26 results.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Change in Directorate 26 May - Board approved reappointment of N. Sivaraman, appointment of Anand Mohan Tiwari, and Chetan Shah as non-executive director.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.